Den europeiske union -
norsk -
EMA (European Medicines Agency)
topotecan teva
teva b.v. - topotekan - ovarian neoplasms; uterine cervical neoplasms; small cell lung carcinoma - antineoplastiske midler - topotecan monotherapy is indicated for the treatment of: , patients with metastatic carcinoma of the ovary after failure of first line or subsequent therapy;, patients with relapsed small cell lung cancer [sclc] for whom re-treatment with the first-line regimen is not considered appropriate. , topotecan i kombinasjon med cisplatin er indisert for pasienter med karsinom i cervix tilbakevendende etter strålebehandling, og for pasienter med stadium ivb sykdom. pasienter med tidligere eksponering for cisplatin krever en vedvarende behandling gratis intervall for å rettferdiggjøre behandling med kombinasjon.
Norge -
norsk -
Statens legemiddelverk
daivobet 50 mikrog/ g / 0.5 mg/ g
leo pharma (2) - kalsipotriolmonohydrat / betametasondipropionat - gel - 50 mikrog/ g / 0.5 mg/ g
Norge -
norsk -
Statens legemiddelverk
fenemal 50 mg
orifarm healthcare a/s - fenobarbital - tablett - 50 mg
Norge -
norsk -
Statens legemiddelverk
prednisolon 20 mg
orifarm healthcare a/s - prednisolon - tablett - 20 mg
Norge -
norsk -
Statens legemiddelverk
prednisolon 2.5 mg
orifarm healthcare a/s - prednisolon - tablett - 2.5 mg
Norge -
norsk -
Statens legemiddelverk
prednisolon 5 mg
orifarm healthcare a/s - prednisolon - tablett - 5 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
insulin lispro sanofi
sanofi winthrop industrie - insulin lispro - sukkersyke - legemidler som brukes i diabetes - for behandling av voksne og barn med diabetes mellitus som krever insulin for vedlikehold av normal glukose homeostase. insulin lispro sanofi er også indikert for den første stabiliseringen av diabetes mellitus.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
insulin aspart sanofi
sanofi winthrop industrie - insulin aspart - sukkersyke - legemidler som brukes i diabetes - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.